A5054830306- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Diabetes Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiac electrophysiology and arrhythmias
- Blood Pressure and Hypertension Studies
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Potassium and Related Disorders
- Hormonal Regulation and Hypertension
- Acute Myocardial Infarction Research
- Cardiovascular Disease and Adiposity
- Cardiac Structural Anomalies and Repair
- Pancreatic function and diabetes
- Health Systems, Economic Evaluations, Quality of Life
- Cardiomyopathy and Myosin Studies
- Cardiovascular Health and Risk Factors
- Cardiac Valve Diseases and Treatments
- Influenza Virus Research Studies
- Erythropoietin and Anemia Treatment
- Metabolism, Diabetes, and Cancer
- Heart Rate Variability and Autonomic Control
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Dialysis and Renal Disease Management
Brigham and Women's Hospital
2016-2025
Harvard University
2016-2025
Baim Institute for Clinical Research
2022-2024
Massachusetts General Hospital
1995-2024
University of Glasgow
2014-2024
Duke University Hospital
2004-2024
Oregon Health & Science University
2015-2024
University of Michigan
2008-2024
National Heart Centre Singapore
2017-2024
British Heart Foundation
2011-2024
We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure a reduced ejection fraction. In previous studies, improved survival such patients.In this double-blind trial, we randomly assigned 8442 class II, III, or IV and an fraction of 40% less to receive either (at dose 200 mg twice daily) 10 daily), addition recommended therapy. The primary outcome was composite death from cardiovascular causes hospitalization for failure, but trial...
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter (SGLT2) reduce the risk a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding effects SGLT2 in established failure and reduced ejection fraction, regardless presence or absence diabetes.
This trial was designed to determine whether cardiac-resynchronization therapy (CRT) with biventricular pacing would reduce the risk of death or heart-failure events in patients mild cardiac symptoms, a reduced ejection fraction, and wide QRS complex.During 4.5-year period, we enrolled followed 1820 ischemic nonischemic cardiomyopathy, an fraction 30% less, duration 130 msec more, New York Heart Association class I II symptoms. Patients were randomly assigned 3:2 ratio receive CRT plus...
Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of angiotensin-receptor blocker valsartan, ACE inhibitor captopril, combination two on in this population patients.
Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.
Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated effects of spironolactone in preserved fraction.In this randomized, double-blind trial, we assigned 3445 symptomatic fraction 45% or more to receive either (15 45 mg daily) placebo. The primary outcome was composite death from cardiovascular causes, aborted cardiac arrest, hospitalization management failure.With mean follow-up 3.3 years,...
RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity humans are uncertain. authors hy...
Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk associated with their use. Experimental research that these drugs may contribute to a prothrombotic state provides support for this concern.We reviewed all potentially serious events among 2035 patients history colorectal neoplasia who were enrolled in trial comparing two doses celecoxib (200 mg or 400 twice daily) placebo the prevention adenomas. All deaths...
Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on outcomes diabetes who had recent acute coronary event.We randomly assigned myocardial infarction or been hospitalized for unstable angina within previous 180 days to receive lixisenatide placebo addition locally determined standards...
Anemia is associated with an increased risk of cardiovascular and renal events among patients type 2 diabetes chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these has not been adequately tested.
The presence of coexisting conditions has a substantial effect on the outcome acute myocardial infarction. Renal failure is associated with one highest risks, but influence milder degrees renal impairment less well defined.As part Valsartan in Acute Myocardial Infarction Trial (VALIANT), we identified 14,527 patients infarction complicated by clinical or radiologic signs heart failure, left ventricular dysfunction, both, and documented serum creatinine measurement. Patients were randomly...
The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with and ejection fraction. effect inhibition in preserved fraction is unclear.
In some randomized trials comparing revascularization strategies for patients with diabetes, coronary-artery bypass grafting (CABG) has had a better outcome than percutaneous coronary intervention (PCI). We sought to discover whether aggressive medical therapy and the use of drug-eluting stents could alter approach diabetes multivessel artery disease.In this trial, we assigned disease undergo either PCI or CABG. The were followed minimum 2 years (median among survivors, 3.8 years). All...
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic a left ventricular ejection fraction 40% or less. Whether SGLT2 are effective in higher remains less certain.
Abstract Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains challenge. We recommend new stepwise diagnostic process, the ‘HFA–PEFF algorithm’. Step 1 (P=Pre-test assessment) is typically performed in ambulatory setting and includes assessment for HF symptoms signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), laboratory tests, electrocardiogram, echocardiography. In absence overt...
This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes chronic kidney disease, or both.In a double-blind fashion, we randomly assigned 8561 (300 mg daily) placebo as an adjunct angiotensin-converting-enzyme angiotensin-receptor blocker. The primary end point composite time death first occurrence cardiac arrest resuscitation; nonfatal myocardial infarction; stroke; unplanned...
Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding (TTR) that induce misfolding and systemic deposition of amyloid. Progressive amyloid accumulation leads to multiorgan dysfunction death. Inotersen, a 2′-O-methoxyethyl–modified antisense oligonucleotide, inhibits hepatic production transthyretin.
Studies showing that drugs inhibit cyclooxygenase-2 (COX-2) reduce the number of colorectal adenomas in animals and patients with familial adenomatous polyposis suggest COX-2 inhibitors may also prevent sporadic neoplasia.We randomly assigned who had removed before study entry to receive placebo (679 patients) or 200 mg (685 400 (671 celecoxib twice daily. Randomization was stratified for use low-dose aspirin. Follow-up colonoscopies were performed at one three years after randomization. The...
Overexpression of cyclooxygenase 2 (COX-2) has been associated with colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition as a chemopreventive intervention.The Prevention Colorectal Sporadic Adenomatous Polyps trial was randomized, placebo-controlled, double-blind study the COX-2 inhibitor celecoxib given daily in single 400-mg dose. At 107 centers 32 countries, we randomly assigned 1561 subjects who had adenomas removed before enrollment receive (933...
Phase I clinical studies have demonstrated the feasibility of implanting autologous skeletal myoblasts in postinfarction scars. However, they failed to determine whether this procedure was functionally effective and arrhythmogenic.This multicenter, randomized, placebo-controlled, double-blind study included patients with left ventricular (LV) dysfunction (ejection fraction < or = 35%), myocardial infarction, indication for coronary surgery. Each patient received either cells grown from a...